Analyst Dismisses ViCAT XR Safety Fears, Expects Strong Growth Despite Recent Stock Weakness

Soleno Therapeutics Inc. (NASDAQ:SLNO) is one of the best upside stocks to buy now. On November 18, Wolfe Research analyst Kalpit Patel initiated coverage of Soleno Therapeutics with an Outperform rating and $75 price target. The stock price has been weak recently due to a sequential slowdown in the number of new patients starting treatment (ViCAT XR). However, Patel noted that the firm’s latest survey data indicates concerns about the treatment’s safety are overblown, and the underlying trend for its use ...